Complement (C3, C4, CH50)

Complement tests measure a group of blood proteins that form one of the immune system's oldest defenses. The most commonly ordered are C3, C4, and a functional test called CH50 (sometimes written CH100), which checks whether the whole classical complement pathway is working. Doctors reach for these tests most often when they suspect an autoimmune disease — especially lupus, where the level of complement in the blood rises and falls in step with how active the disease is. They are also used to investigate certain kidney inflammations, some forms of vasculitis, unexplained recurrent infections, and a swelling condition called hereditary angioedema. This page explains, in plain language, what the complement system does, what each test looks at, why your doctor might order one, and how to make sense of a high or low result — including the quirk that these proteins are fragile and can read falsely low if the blood sample is not handled quickly.


Table of Contents

  1. What the Complement System Is
  2. What the Complement Tests Measure
  3. Why Complement Tests Are Ordered
  4. Complement and Lupus
  5. How to Interpret the Results
  6. Complement in Newer Contexts
  7. How the Test Is Done and Why Handling Matters
  8. Related Tests
  9. When to Talk to a Doctor
  10. Research Papers
  11. Connections
  12. Featured Videos

What the Complement System Is

The complement system is a cascade of roughly 30 proteins that circulate quietly in your blood, waiting. Together they are part of the innate immune system — the fast, built-in defense you are born with, as opposed to the slower, learned immunity of antibodies. The name comes from the early days of immunology, when scientists noticed these proteins "complemented" (helped) antibodies finish the job of killing microbes. More than a century later, we know they do far more than assist.

Complement has three main jobs, and it is easiest to remember them as three verbs:

These jobs can be switched on through three different starting routes, all of which funnel into the same central protein, C3:

The classical pathway

Triggered when antibodies latch onto a target and the complement protein C1 recognizes them. This is the antibody-linked route, and it is the one most relevant to autoimmune diseases like lupus, where antibody-based "immune complexes" set complement off.

The lectin pathway

Triggered when specialized proteins recognize sugar patterns on the surface of microbes — no antibody required. It works much like the classical pathway once it gets going.

The alternative pathway

Always simmering at a low level (a state called "tickover"), constantly probing surfaces. On your own healthy cells it is quickly shut down by protective proteins; on a foreign surface it amplifies rapidly. This built-in amplification is powerful, which is also why problems with the alternative pathway's brakes can cause serious disease.

What the Complement Tests Measure

"Complement testing" is not one test but a small family. Your doctor may order one piece or several, depending on the question:

Reference ranges depend heavily on the laboratory and the method it uses, so always read your result against the range printed on your report. As a rough orientation only, many adult labs report values in the neighborhood of:

Why Complement Tests Are Ordered

Complement is not part of a routine checkup. It is ordered when a specific clinical picture raises a specific question. The main reasons include:

Complement and Lupus

If there is one story that explains why complement testing exists in everyday medicine, it is lupus. In active lupus, the immune system forms clumps of antibodies bound to the body's own material — immune complexes. These complexes switch on the classical pathway again and again, and the complement proteins get used up faster than the body can replace them. The result is a measurable drop in C3 and C4 in the blood.

Because of this, C3 and C4 act as a rough dashboard for disease activity. When lupus flares — particularly when it inflames the kidneys (lupus nephritis) — C3 and C4 tend to fall, and as treatment brings the disease under control, they tend to climb back toward normal. Watching the trend over time, alongside symptoms and other tests, is often more informative than any single reading.

It is important to be honest about the limits, though. Complement levels are useful but imperfect markers. Some people run a genetically low baseline C4 even when well, so their "normal" is lower than the textbook range. Others can flare without a dramatic complement drop. Research looking closely at C3 and C4 as biomarkers of lupus kidney flares has found the relationship real but noisy — which is exactly why doctors interpret them in context rather than treating a number in isolation.

How to Interpret the Results

The single most useful thing to understand is that, in complement, low is usually the interesting result. That is the opposite of many other blood tests, where high values raise the most concern.

Low complement

A low C3, low C4, or low CH50 generally points to one of two situations:

The pattern of which proteins are low can itself be a clue. A low C4 with a relatively preserved C3, for example, is a hint toward the classical pathway and is part of the picture in hereditary angioedema, whereas a low C3 with normal C4 shifts attention toward the alternative pathway.

High complement

A high complement level is usually far less exciting. Complement proteins are acute-phase reactants, meaning they naturally rise during inflammation, infection, injury, or stress — much like other markers your body pushes up when it is fighting something. A high C3 or C4 by itself rarely points to a specific disease and is generally not treated as a meaningful finding on its own.

The acute-phase nuance worth knowing

Because complement rises with general inflammation, there is a subtle trap in someone with an inflammatory disease like lupus. If a flare is pushing complement down through consumption while inflammation is simultaneously pushing it up, the two effects can partly cancel out. A result that reads "normal" might actually be relatively low for that person at that moment. This is another reason clinicians favor tracking the trend and pairing complement with more specific tests rather than judging a lone value against a fixed range.

Complement in Newer Contexts

Over the past two decades, complement has moved from a niche lab test into the center of some remarkable treatments, and it is worth mentioning these honestly and briefly because patients increasingly encounter them.

Both are now treated with complement-blocking drugs — the first was eculizumab, later joined by longer-acting ravulizumab — which switch off the terminal part of the cascade. These medicines were genuine breakthroughs for conditions that were once often fatal. Because shutting down terminal complement leaves a person vulnerable to Neisseria (meningococcal) infection, meningococcal vaccination is required before starting them. These are highly specialized therapies managed by hematologists and nephrologists; complement measurements around them are part of specialist care rather than something to interpret at home.

How the Test Is Done and Why Handling Matters

From your side, the test could not be simpler: it is a standard blood draw from a vein in the arm, and no fasting or special preparation is needed. The complexity is all in the laboratory, and there is one practical point every patient should know.

Complement proteins are fragile. They begin to break down (a process called in vitro complement activation) if the blood sample is left sitting at warm temperatures before it is processed. When that happens, the proteins are degraded in the tube rather than in your body — and the result comes back falsely low. For this reason, laboratories that run complement tests spin the sample and separate or freeze the serum promptly, and functional tests like CH50 are especially sensitive to sloppy handling. If a complement result looks surprisingly low but does not fit the clinical picture, a mishandled specimen is one of the first things a good clinician will consider, and the simplest next step is often to repeat the test with careful handling.

The other practical point is that reference ranges and even the units vary substantially between laboratories and methods. A number that is "low" at one lab might sit inside the range at another. Always interpret your result against the reference range printed on your own report, and be cautious about comparing values drawn at different labs.

Complement is almost never interpreted alone. It is usually one instrument in a small orchestra of tests chosen to answer the same question:

When to Talk to a Doctor

Complement tests are not screening tests you would order for yourself, and their results are genuinely difficult to interpret without the clinical story that prompted them. A low value can mean a flare of a known autoimmune disease, a brand-new diagnosis, an inherited deficiency, or simply a sample that sat too long on the way to the lab — and only your doctor, seeing the whole picture, can tell which.

Reach out to your clinician promptly if you have a diagnosis such as lupus and your complement levels are falling, if you have unexplained recurrent serious infections, or if you have episodes of unexplained swelling of the lips, face, hands, or throat, which can be an emergency if breathing is affected. If you are handed a complement result, useful questions to ask include: Why did you order this? What does my result mean in the context of my symptoms? Should it be repeated or tracked over time? What other tests go with it? Understanding that "low is the meaningful direction," that the proteins are fragile in the tube, and that trends matter more than single numbers will help you have a more informed conversation.

Research Papers

  1. Walport MJ. Complement. First of two parts. New England Journal of Medicine. 2001;344(14):1058–1066. doi:10.1056/NEJM200104053441406 — the classic, accessible overview of how the complement system is built and activated.
  2. Walport MJ. Complement. Second of two parts. New England Journal of Medicine. 2001;344(15):1140–1144. doi:10.1056/NEJM200104123441506 — companion review covering complement's role in disease, including autoimmunity and deficiency.
  3. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nature Immunology. 2010;11(9):785–797. doi:10.1038/ni.1923 — a widely cited modern synthesis of complement's many roles beyond simple defense.
  4. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement System Part I — Molecular Mechanisms of Activation and Regulation. Frontiers in Immunology. 2015;6:262. doi:10.3389/fimmu.2015.00262 — a clear open-access walk-through of the three pathways and their brakes.
  5. Sturfelt G, Truedsson L. Complement in the immunopathogenesis of rheumatic disease. Nature Reviews Rheumatology. 2012;8(8):458–468. doi:10.1038/nrrheum.2012.75 — reviews why complement is consumed in lupus and other rheumatic conditions.
  6. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Advances in Immunology. 2000;76:227–324. doi:10.1016/S0065-2776(01)76021-X — explains the paradox that inherited complement deficiency actually predisposes to lupus.
  7. Birmingham DJ, Irshaid F, Nagaraja HN, et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus. 2010;19(11):1272–1280. doi:10.1177/0961203310371154 — an honest look at how well (and how imperfectly) C3 and C4 track lupus kidney flares.
  8. Zuraw BL. Hereditary angioedema. New England Journal of Medicine. 2008;359(10):1027–1036. doi:10.1056/NEJMcp0803977 — clinical review of the condition in which low C4 and C1-inhibitor testing are central.
  9. Cicardi M, Zuraw BL. Angioedema due to bradykinin dysregulation. Journal of Allergy and Clinical Immunology: In Practice. 2018;6(4):1132–1141. doi:10.1016/j.jaip.2018.04.022 — connects the complement brake C1 inhibitor to the mechanism of angioedema.
  10. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine. 2006;355(12):1233–1243. doi:10.1056/NEJMoa061648 — the trial that launched complement-blocking therapy for PNH.
  11. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. New England Journal of Medicine. 2013;368(23):2169–2181. doi:10.1056/NEJMoa1208981 — established complement blockade as treatment for aHUS.
  12. Ling M, Murali M. Analysis of the complement system in the clinical immunology laboratory. Clinics in Laboratory Medicine. 2019;39(4):579–590. doi:10.1016/j.cll.2019.07.006 — a practical guide to how C3, C4, and CH50 are measured and interpreted, including handling pitfalls.

Back to Table of Contents

Connections

Back to Table of Contents